Elasmogen
Latest round
- Seed
Last raised
- Mar 2017
Total raised
- Undisclosed
Investors
- 2
About Elasmogen
Elasmogen Ltd.Founded in 2016, Elasmogen Ltd. is headquartered in Aberdeen, UK. The company specializes in developing therapeutic solutions through its proprietary soloMER technology, which includes unique antibody-like proteins derived from shark immune systems. Caroline Barelle serves as both CEO and founder, with a history of involvement in biotechnology.Elasmogen Ltd specializes in the discovery and development of therapeutics utilizing their proprietary biologics platform known as soloMERs®. These small, unique antibody-like proteins, derived from the immune systems of sharks, are designed to target a range of diseases, particularly autoimmune disorders and various forms of cancer. The soloMER technology enables the creation of multi-functional therapeutic products with differentiated binding interactions, thereby offering novel mechanisms of action. These therapeutics have potential applications in clinical settings, addressing unmet medical needs by improving patient outcomes and quality of life.Elasmogen generates revenue primarily through partnerships and licensing agreements for its patented soloMER technology and related products. The business structure is primarily B2B, where transactions typically involve collaborative agreements with pharmaceutical companies seeking to develop novel therapeutics leveraging Elasmogen's unique capabilities. Revenue streams may derive from upfront licensing fees, milestone payments, and royalties based on product sales. The company’s flagship products, particularly those developed for cancer treatment, are sold under licensing agreements, with a focus on creating tailored solutions that meet partner-specific requirements. The company aims to expand into North America and Asia by 2025, capitalizing on its existing partnerships and exploring new opportunities to enhance its market presence. This strategic expansion will be complemented by ongoing research and development efforts to drive innovation in therapeutics.
Who invested in Elasmogen
2 investors across 1 round
See all investors in Elasmogen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Mar 16, 2017
Amount
Undisclosed
Investors
Questions about Elasmogen
Who invested in Elasmogen?
Elasmogen has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Elasmogen raised?
Elasmogen has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Elasmogen last raise money?
Elasmogen's most recent round on record is a Seed, in Mar 2017.
What does Elasmogen do?
Elasmogen is a pharmaceuticals company.
Where is Elasmogen headquartered?
Elasmogen is headquartered in Aberdeen, UK.
Which VCs invest in companies like Elasmogen?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back pharmaceuticals companies at Elasmogen's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Seed
Raising like Elasmogen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.